News

PAI Pharma buys Nexus to grow hospital injectables portfolio

What's the deal? PAI PharmaDealroom has a profile for this one. Try Dealroom → has acquired Nexus PharmaceuticalsDealroom has a profile for this one. Try Dealroom →, a US company that develops and commercialises injectable medicines for critical care, oncology, and other hospital settings. The deal, announced November 12, 2026, has undisclosed terms. Nexus brings a commercial portfolio of more than 20 hospital injectable products.

Why now? US hospitals continue to face recurring sterile-drug shortages, which rose for a third consecutive quarter in Q2 2026, though they remained below their 2024 peak. Nexus already supplies therapies that have historically faced supply shortages.

What's the endgame? PAI, a portfolio company of Olympus PartnersDealroom has a profile for this one. Try Dealroom →, wants a broader portfolio of essential medicines and a bigger presence in hospital and sterile injectable markets. It makes oral liquid medicines alongside ready-to-use sterile injectables.

What changes? The deal adds Nexus's established customer relationships and development expertise to PAI's growing sterile injectable business. That business includes PAI's recent acquisition of Nivagen and its aseptic manufacturing site in Sacramento. William Blair advised PAI on the transaction.

What could go wrong? The acquisition expands US production capacity and product breadth in a shortage-prone segment. But its impact on actual supply depends on products clearing development and reaching commercial production.

The signal: The deal reflects steady consolidation among US drugmakers racing to build domestic sterile-injectable capacity. For hospitals battling persistent shortages, more suppliers with local manufacturing could ease a long-running supply problem — if the pipeline delivers.

Read more: prnewswire.com

Image credit: Generated with Gemini

More top stories